GlassScriptPhysician profile
Kenneth Scott Pacer
NPI 1033237300
$132,601.69
in general payments reported to CMS, 2019-2025
14 companies · $34K in 2025
The $34K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $2,885 · 2021: $15K · 2022: $5,668 · 2023: $36K · 2024: $24K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $75K · Honoraria: $11K · Travel and Lodging: $4,913 · Food and Beverage: $3,451 · Education: $32.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $74,658.75 |
| Honoraria | $11,150.00 |
| Travel and Lodging | $4,912.84 |
| Food and Beverage | $3,450.85 |
| Education | $32.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $74,772.53 | 2019-2025 | Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $49,478.03 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $7,499.83 | 2019-2022 | |
| Corium, LLC | $330.05 | 2021-2024 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $179.32 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $139.33 | 2023-2024 | Invega Sustenna |
| Neurocrine Biosciences, INC. | $87.14 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.70 | 2025 | Abilify Asimtufii |
| Lundbeck LLC | $25.09 | 2025 | Rexulti |
| Shire North American Group INC | $16.00 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.91 | 2022 | |
| Vertical Pharmaceuticals, LLC | $14.08 | 2019 | |
| Adlon Therapeutics L.P. | $12.73 | 2021 | |
| Validus Pharmaceuticals LLC | $5.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Pacer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.